Physician profile

Peter Dipasco

Surgical Oncology · Saint Louis, MO

NPI 1659491314

$246,626.26

in general payments reported to CMS, 2019-2025

65 companies · $50K in 2025

The $50K reported for 2025 was more than what 99% of Surgical Oncology providers received nationally (typical 2025 total: $288).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$125,773.78
Travel and Lodging$7,297.18
Food and Beverage$6,471.50
Education$98.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medical Device Business Services, INC. $149,368.59 2019-2025 Neuflex, Zip Pen, Megadyne
Ethicon US, LLC $53,906.73 2019-2025 Certus 140, Megadyne, Vistaseal
Ethicon INC. $25,037.36 2019-2025 Certus 140
Ethicon Endo-Surgery INC. $12,358.27 2023-2024 Neuflex, Certus 140
Histosonics, INC. $938.96 2024
Regeneron Healthcare Solutions, INC. $368.78 2022-2025 Libtayo
Janssen Biotech, INC. $312.06 2021-2025 Tecvayli, Talvey, Darzalex
Hologic Sales and Service, LLC $306.13 2024-2025 Coolseal Generator
Merck Sharp & Dohme LLC $294.18 2021-2025 Keytruda, Lynparza, Keytruda Qlex
Tempus Ai, INC $251.10 2024
Astrazeneca Pharmaceuticals Lp $235.24 2021-2025 Imfinzi, Calquence, Enhertu
Daiichi Sankyo INC. $218.87 2022-2025 Enhertu, Injectafer
Intera Oncology, INC $175.02 2024 Intera
Stryker Corporation $173.18 2024 Stryker
Dilon Technologies, INC. $156.31 2025 Hemoblast Bellows
Show all 65 companies
CompanyGeneral paymentsYearsTop products
Genentech USA, INC. $154.07 2023-2025 Polivy, Tecentriq, Lunsumio
Pfizer INC. $140.80 2022-2024
Takeda Pharmaceuticals U.S.A., INC. $136.14 2022-2025 Iclusig, Fruzaqla, Alunbrig
Abbvie INC. $127.31 2021-2025 Venclexta
Incyte Corporation $126.38 2020-2025 Jakafi, Niktimvo, Monjuvi
Novo Nordisk INC $125.00 2022
Seagen INC. $119.69 2021-2023 Tukysa
Amgen INC. $108.66 2021-2023 Lumakras, Nplate, Xgeva
Novartis Pharmaceuticals Corporation $106.52 2022-2024
Siemens Medical Solutions USA, INC. $105.81 2025 Microthermx Microwave Ablation System
Lilly USA, LLC $92.52 2023-2025 Verzenio, Jaypirca, Retevmo
Eisai INC. $80.63 2021-2023
Bayer Healthcare Pharmaceuticals INC. $69.52 2023-2024
Taiho Oncology, INC. $69.32 2022-2025
Myriad Genetic Laboratories, INC. $68.85 2021-2023 Myrisk
Puma Biotechnology, INC. $59.17 2021-2024
Genzyme Corporation $47.75 2022-2023
Springworks Therapeutics, INC. $47.39 2025 Ogsiveo
Mirati Therapeutics, INC. $41.81 2023-2024 Krazati
Sobi, INC $40.70 2022-2025
Kyowa Kirin, INC. $40.66 2021-2023 Poteligeo
Adc Therapeutics America, INC. $39.66 2022-2023
Blueprint Medicines Corporation $39.32 2022-2023 Ayvakit
Servier Pharmaceuticals LLC $34.78 2021-2024
Global Blood Therapeutics, INC. $32.44 2021-2022
Galvanize Therapeutics, INC $29.24 2023 Aliya System
Ets Wound Care LLC $29.16 2024 Mirragen Advanced Wound Matrix
Astellas Pharma US INC $27.50 2025 Vyloy
G1 Therapeutics, INC. $22.02 2023 Cosela
Intuitive Surgical, INC. $21.90 2022
Beigene USA, INC. $21.83 2025 Tevimbra
Medtronic, INC. $21.52 2025 Emprint
Blue Earth Diagnostics $20.67 2021
Immunogen, INC. $19.98 2023 Elahere
Emd Serono, INC. $19.96 2021
Octapharma USA, INC. $19.28 2024 Octagam Immune Globulin (Human)
Aveo Pharmaceuticals, INC. $18.52 2025
Morphosys, US INC. $18.22 2021
Coherus Oncology, INC. $17.68 2021
Dova Pharmaceuticals $17.56 2021
E.R. Squibb & Sons, L.L.C. $16.82 2021
Melinta Therapeutics, LLC $16.28 2024 Kimyrsa, Rezzayo
Tersera Therapeutics LLC $16.02 2023 Zoladex
Pharmacosmos Therapeutics INC. $15.97 2024 Cosela
Emmaus Medical, INC. $15.51 2024 Endari
Gilead Sciences, INC. $14.57 2025 Trodelvy
Epizyme, INC. $13.33 2021
Adaptive Biotechnologies Corporation $12.91 2021
Sun Pharmaceutical Industries INC. $12.36 2021
Pharmaand Gmbh $11.77 2025 Rubraca

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Dipasco

$246,626.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Medical Device Business Services, INC.
Context
The $50K reported for 2025 was more than what 99% of Surgical Oncology providers received nationally (typical 2025 total: $288).

https://glasscript.com/doctor/211195/peter-dipasco

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.